



**Supplemental Figure 2:** Forest plot of clinical studies on pharmacological conditioning in patients with acute myocardial infarction and with biomarker release or imaging techniques to estimate infarct size as end-point. The zero represents the mean value, and the gray bars represent the standard error of the mean for the placebo group. Closed squares represent significantly reduced infarct size ( $\tilde{x} \pm \text{SEM}$ ), open squares represent non-significant changes.

The star on the midline is used when no information was given to the standard error of the mean. ANP = atrial natriuretic peptide; CK(-MB) = creatine kinase (muscle-brain); drug = pharmacological conditioning group; Fx06 = peptide derived from the neo-N-terminus of fibrin; G-CSF = granulocyte-colony stimulating factor; GIK = glucose-insulin-potassium; (hs)Tn(I/T) = (high sensitive) troponin (I/T); IGF1 = insulin-like growth factor 1; LeukArrest = rovelizumab; n.s. = not significant; MRI = magnetic resonance imaging; MTP-131 = cardioliipin-targeting peptide; PLA = placebo group; SNP = sodium nitroprusside; SPECT = single-photon emission computed tomography; TRO40303 = 3,5-seco-4-nor-cholestan-5-one oxime-3-ol; \* = dual anti platelet therapy

## References

Achilli, F., Pontone, G., Bassetti, B., Squadroni, L., Campodonico, J., Corrada, E., et al. (2019). G-CSF for Extensive STEMI: Results from the STEM-AMI OUTCOME CMR Substudy. *Circulation Research*, <https://doi.org/10.1161/CIRCRESAHA.118.314617>

Atar, D., Arheden, H., Berdeaux, A., Bonnet, J.L., Carlsson, M., Clemmensen, P., et al. (2015). Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. *European Heart Journal*, 36, 112-119. <https://doi.org/10.1093/eurheartj/ehu331>.

Atar, D., Petzelbauer, P., Schwitter, J., Huber, K., Rensing, B., Kasprzak, J.D., et al. (2009). Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. *Journal of the American College of Cardiology*, 53, 720-729. <https://doi.org/10.1016/j.jacc.2008.12.017>

Bates, E., Bode, C., Costa, M., Gibson, C.M., Granger, C., Green, C., et al. (2008). Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. *Circulation*, 117, 886-896. <https://doi.org/10.1161/CIRCULATIONAHA.107.759167>

Bulluck, H., Froehlich, G.M., Nicholas, J.M., Mohdnazri, S., Gamma, R., Davies, J., et al. (2019). Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to

minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial. *American Heart Journal*, 211, 60-67. <https://doi.org/10.1016/j.ahj.2019.02.005>

Campodonico, J., Cosentino, N., Milazzo, V., Rubino, M., De Metrio, M., Marana, I., et al. (2018). Impact of chronic antiplatelet therapy on infarct size and bleeding in patients with acute myocardial infarction. *Journal of Cardiovascular Pharmacology and Therapeutics*, 23, 407-413. <https://doi.org/10.1177/1074248418769636>

Caplice, N.M., DeVoe, M.C., Choi, J., Dahly, D., Murphy, T., Spitzer, E., et al. (2018). Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI). *American Heart Journal*, 200, 110-117. <https://doi.org/10.1016/j.ahj.2018.03.018>

Chen, W.R., Chen, Y.D., Tian, F., Yang, N., Cheng, L.Q., Hu, S.Y., et al. (2016). Effects of liraglutide on reperfusion injury in patients with ST-segment-elevation myocardial infarction. *Circulation Cardiovascular Imaging*, 9, e005146. <https://doi.org/10.1161/CIRCIMAGING.116.005146>

Cung, T.T., Morel, O., Cayla, G., Rioufol, G., Garcia-Dorado, D., Angoulvant, D., et al. (2015). Cyclosporine before PCI in patients with acute myocardial infarction. *The New England Journal of Medicine*, 373, 1021-1103. <https://doi.org/10.1056/NEJMoa1505489>

Desmet, W., Bogaert, J., Dubois, C., Sinnaeve, P., Adriaenssens, T., Pappas, C., et al. (2011). High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. *European Heart Journal*, 32, 867-877. <https://doi.org/10.1093/eurheartj/ehq492>.

Dominguez-Rodriguez, A., Abreu-Gonzalez, P., de la Torre-Hernandez, J.M., Gonzalez-Gonzalez, J., Garcia-Camarero, T., Consuegra-Sanchez, L., et al. (2017). Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: Results of the melatonin adjunct in the acute myocardial infarction treated with angioplasty trial. *Journal of Pineal Research*, 62, e12374. <https://doi.org/10.1111/jpi.12374>

Ekeloef, S., Halladin, N., Fonnes, S., Jensen, S.E., Zaremba, T., Rosenberg, J., et al. (2017). Effect of intracoronary and intravenous melatonin on myocardial salvage index in patients

with ST-elevation myocardial infarction: a randomized placebo controlled trial. *Journal of Cardiovascular Translational Research*, 10, 470-479. <https://doi.org/10.1007/s12265-017-9768-7>

Engstrøm, T., Nepper-Christensen, L., Helqvist, S., Klovgaard, L., Holmvang, L., Jørgensen, E., et al. (2018). Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial. *Heart*, 104, 1593-1599. <https://doi.org/10.1136/heartjnl-2017-312774>

Er, F., Dahlem, K.M., Nia, A.M., Erdmann, E., Waltenberger, J., Hellmich, M., et al. (2016). Randomized control of sympathetic drive with continuous esmolol in patients with acute ST-segment elevation myocardial infarction. The BEtA-Blocker Therapy in acute myocardial infarction (BEAT-AMI) Trial. *Journal of the American College of Cardiology: Cardiovascular Intervention*, 9, 231-240. <https://doi.org/10.1016/j.jcin.2015.10.035>

Faxon, D.P., Gibbons, R.J., Chronos, N.A., Gurbel, P.A., & Sheehan, F. (2002). The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. *Journal of the American College of Cardiology*, 40, 1199-1204. [https://doi.org/10.1016/S0735-1097\(02\)02136-8](https://doi.org/10.1016/S0735-1097(02)02136-8)

Fokkema, M.L., Vlaar, P.J., Vogelzang, M., Gu, Y.L., Kampinga, M.A., de Smet, B.J., et al. (2009). Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. *Circulation Cardiovascular Intervention*, 2, 323-329. <https://doi.org/doi:10.1161/CIRCINTERVENTIONS.109.858977.109.858977>.

Garcia-Dorado, D., Garcia-Del-Blanco, B., Otaegui, I., Rodriguez-Palomares, J., Pineda, V., Gimeno, F., et al. (2014). Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: A randomized controlled clinical trial. *International Journal of Cardiology*, 177, 935-941. <https://doi.org/10.1016/j.ijcard.2014.09.203>.

Ghaffari, S., Kazemi, B., Toluey, M., & Sepehrvand, N. (2013). The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction. *Cardiovascular Therapeutics*, 31, e34-39. <https://doi.org/10.1111/1755-5922.12010>

Gibson, C.M., Giugliano, R.P., Kloner, R.A., Bode, C., Tendera, M., Janosi, A., et al. (2015). EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. *European Heart Journal*, 37, 1296-1303. <https://doi.org/10.1093/eurheartj/ehv597>

Granger, C.B., Mahaffey, K.W., Weaver, W.D., Theroux, P., Hochman, J.S., Fillo, T.G., et al. (2003). Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction. The COMPLEMENT inhibition in myocardial infarction treated with angioplasty (COMMA) trial. *Circulation*, 108, 1184-1190. <https://doi.org/10.1161/01.CIR.0000087447.12918.85>

Gwag, H.B., Kim, E.K., Park, T.K., Lee, J.M., Yang, J.H., Song, Y.B., et al. (2017). Cardioprotective effects of intracoronary morphine in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: A prospective, randomized trial. *J Am Heart Assoc*, 6, e005426. <https://doi.org/10.1161/JAHA.116.005426>

Ibanez, B., Macaya, C., Sanchez-Brunete, V., Pizarro, G., Fernandez-Friera, L., Mateos, A., et al. (2013). Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. *Circulation*, 128, 1495-1503. <https://doi.org/10.1161/CIRCULATIONAHA.113.003653>.

Janssens, S.P., Bogaert, J., Zalewski, J., Toth, A., Adriaenssens, T., Belmans, A., et al. (2018). Nitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial. *European Heart Journal*, 39, 2717-2725. <https://doi.org/10.1093/eurheartj/ehy232>

Jones, D.A., Pellaton, C., Velmurugan, S., Andiapan, M., Antoniou, S., van Eijl, S., et al. (2015). Randomized phase 2 trial of intra-coronary nitrite during acute myocardial infarction. *Circulation Research*, 116, 437-447. <https://doi.org/10.1161/CIRCRESAHA.116.305082>.

Karlsson, J.E., El-Saadi, W., Ali, M., Puskar, W., Skogvard, P., Engvall, J.E., et al. (2015). Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in

patients with ST-segment elevation myocardial infarction. *European Heart Journal of Cardiovascular Pharmacotherapy*, 1, 39-45. <https://doi.org/10.1093/ehjcvp/pvu021>

Kitakaze, M., Asakura, M., Kim, J., Shintani, Y., Asanuma, H., Hamasaki, T., et al. (2007). Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. *The Lancet*, 370, 1483-1493. [https://doi.org/10.1016/S0140-6736\(07\)61634-1](https://doi.org/10.1016/S0140-6736(07)61634-1).

Le Corvoisier, P., Gallet, R., Lesault, P.F., Audureau, E., Paul, M., Ternacle, J., et al. (2018). Intra-coronary morphine versus placebo in the treatment of acute ST-segment elevation myocardial infarction: the MIAMI randomized controlled trial. *British Medical Journal Cardiovascular Disorders*, 18, 193. <https://doi.org/10.1186/s12872-018-0936-8>

Lincoff, A.M., Roe, M., Aylward, P., Galla, J., Rynkiewicz, A., Guetta, V., et al. (2014). Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. *European Heart Journal*, 35, 2516-2523. <https://doi.org/10.1093/eurheartj/ehu177>.

Lonborg, J., Vejstrup, N., Kelbaek, H., Bøtker, H.E., Kim, W.Y., Mathiasen, A.B., et al. (2012). Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. *European Heart Journal*, 33, 1491-1499. <https://doi.org/10.1093/eurheartj/ehr309>

Mahaffey, K.W., Granger, C.B., Nicolau, J.C., Ruzylo, W., Weaver, W.D., Theroux, P., et al. (2003). Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction. The COMPLEMENT inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. *Circulation*, 108, 1176-1183. <https://doi.org/10.1161/01.CIR.0000087404.53661.F8>

Mahaffey, K.W., Puma, J.A., Barbagelata, A., DiCarli, M.F., Leesar, M.A., Browne, K.F., et al. (1999). Adenosine as an adjunct thrombolytic therapy for acute myocardial infarction. *Journal of the American College of Cardiology*, 34, 1711-1720.

Marenzi, G., Cosentino, N., Cortinovis, S., Milazzo, V., Rubino, M., Cabiati, A., et al. (2015). Myocardial infarct size in patients on long-term statin therapy undergoing primary

percutaneous coronary intervention for ST-elevation myocardial infarction. *American Journal of Cardiology*, 116, 1791-1797. <https://doi.org/10.1016/j.amjcard.2015.09.016>

Marzilli, M., Orsini, E., Marraccini, P., & Testa, R. (2000). Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. *Circulation*, 101, 2154-2159. <https://doi.org/10.1161/01.CIR.101.18.2154>

McCartney, P.J., Eteiba, H., Maznyczka, A.M., McEntegart, M., Greenwood, J.P., Muir, D.F., et al. (2019). Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial. *Journal of the American Medical Association*, 321, 56-68. <https://doi.org/10.1001/jama.2018.19802>

Najjar, S.S., Rao, S.V., Melloni, C., Raman, S.V., Povsic, T.J., Melton, L., et al. (2011). Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. *Journal of the American Medical Association*, 305, 1863-1872. <https://doi.org/10.1001/jama.2011.592>

Nazir, S.A., McCann, G.P., Greenwood, J.P., Kunadian, V., Khan, J.N., Mahmoud, I.Z., et al. (2016). Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial. *European Heart Journal*, 37, 1910-1919. <https://doi.org/10.1093/eurheartj/ehw136>

Niccoli, G., Rigattieri, S., De Vita, M.R., Valgimigli, M., Corvo, P., Fabbicchi, F., et al. (2013). Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: The REOPEN-AMI Study. *Journal of the American College of Cardiology Cardiovascular Intervention* 6, 580-589.  
<https://doi.org/10.1016/j.jcin.2013.02.009>

Nozari, Y., Eshraghi, A., Talasaz, A.H., Bahremand, M., Salamzadeh, J., Salarifar, M., et al. (2018). Protection from reperfusion injury with intracoronary N-acetylcysteine in patients with STEMI undergoing primary percutaneous coronary intervention in a cardiac tertiary center. *American Journal of Cardiovascular Drugs : Drugs, Devices, and other Interventions*, 18, 213-221. <https://doi.org/10.1007/s40256-017-0258-8>

Ott, I., Schulz, S., Mehilli, J., Fichtner, S., Hadamitzky, M., Hoppe, K., et al. (2010). Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. *Circulation Cardiovascular Intervention*, 3, 408-413. <https://doi.org/10.1161/CIRCINTERVENTIONS.109.904425>

Ottani, F., Latini, R., Staszewsky, L., La Vecchia, L., Locuratolo, N., Sicuro, M., et al. (2016). Cyclosporine A in reperfused myocardial infarction. The multicenter, controlled, open-label CYCLE Trial. *Journal of the American College of Cardiology*, 67, 365-374. <https://doi.org/10.1016/j.jacc.2015.10.081>

Pasupathy, S., Tavella, R., Grover, S., Raman, B., Procter, N.E.K., Du, Y.T., et al. (2017). Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction reduces myocardial infarct size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]). *Circulation*, 136, 894-903. <https://doi.org/10.1161/CIRCULATIONAHA.117.027575>

Piot, C., Croisille, P., Staat, P., Thibault, H., Rioufol, G., Mewton, N., et al. (2008). Effect of cyclosporine on reperfusion injury in acute myocardial infarction. *The New England Journal of Medicine*, 359, 473-481. <https://doi.org/10.1056/NEJMoa071142>.

Roolvink, V., Ibanez, B., Ottervanger, J.P., Pizarro, G., van Royen, N., Mateos, A., et al. (2016). Early administration of intravenous beta blockers in patients with ST-elevation myocardial infarction before primary PCI. *Journal of the American College of Cardiology*, 67, 2705-2715. <https://doi.org/10.1016/j.jacc.2016.03.522>

Ross, A., Gibbons, R.J., Stone, G.W., Kloner, R.A., & Alexander, R.W. (2005). A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD II). *Journal of the American College of Cardiology*, 45, 1775-1780. <https://doi.org/10.1016/j.jacc.2005.02.061>.

Selker, H.P., Beshansky, J.R., Sheehan, P.R., Massaro, J.M., Griffith, J.L., D'Agostino, R.B., et al. (2012). Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: The IMMEDIATE Randomized Controlled Trial. *Journal of the American Medical Association*, 307, 1925-1933. <https://doi.org/10.1001/jama.2012.426>



Seo, W.W., Suh, J.W., Oh, I.Y., Yoon, C.H., Cho, Y.S., Youn, T.J., et al. (2019). Efficacy of IntraCoronary Erythropoietin delivery BEfore Reperfusion-Gauging infarct size in patients with acute ST-segment elevation myocardial infarction (ICEBERG). *International Heart Journal*, 60, 255-263. <https://doi.org/10.1536/ihj.18-035>

Siddiqi, N., Neil, C., Bruce, M., MacLennan, G., Cotton, S., Papadopoulou, S., et al. (2014). Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). *European Heart Journal*, 35, 1255-1262. <https://doi.org/10.1093/eurheartj/ehu096>.

Stone, G.W., Maehara, A., Witzenbichler, B., Godlewski, J., Parise, H., Dambrink, J.H., et al. (2012). Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. *Journal of the American Medical Association*, 307, 1817-1826. <https://doi.org/10.1001/jama.2012.421>

Theroux, P., Chaitman, B.R., Danchin, N., Erhardt, L., Meinertz, T., Schroeder, J.S., et al. (2000). Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. *Circulation*, 102, 3032-3038. <https://doi.org/10.1161/01.CIR.102.25.3032>

Voors, A.A., Belonje, A.M., Zijlstra, F., Hillege, H.L., Anker, S.D., Slart, R.H., et al. (2010). A single dose of erythropoietin in ST-elevation myocardial infarction. *European Heart Journal*, 31, 2593-2600. <https://doi.org/10.1093/eurheartj/ehq304>

Woo, J.S., Kim, W., Ha, S.J., Kim, J.B., Kim, S.J., Kim, W.S., et al. (2013). Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of exenatide myocardial protection in revascularization study. *Arteriosclerotic Thrombosis Vascular Biology*, 33, 2252-2260. <https://doi.org/10.1161/ATVBAHA.113.301586>.

Zeymer, U., Suryapranata, H., Monassier, J.P., Opolski, G., Davies, J., Rasmanis, G., et al. (2001). The Na<sup>+</sup>/H<sup>+</sup> exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. *Journal of the American College of Cardiology*, 38, 1644-1650.